Q&A: Page 2
Exclusive interviews with industry leaders
-
Real Chemistry/PharmaVoice
Lessons from improv: Shankar Narayanan's 'yes, and' approach to healthcare leadership
Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.
Taren Grom • April 4, 2022 -
Stock via Getty Images
Time-saving tech lights Alcon's path into digital innovation
Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a North Star when developing digital tools.
Kim Ribbink • April 4, 2022 -
Sangamo Therapeutics
Sangamo has its finger on the next evolution of gene editing
Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.
Taren Grom • March 31, 2022 -
Stock via Getty Images
Rare Patient Voice's president is striving to create a five-star experience for patients
Successful clinical trial recruitment depends on listening to and empowering patients.
Kim Ribbink • March 23, 2022 -
Stock via Getty Images
Why Astellas is adopting a 'focus area approach' to partnerships
Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.
Kim Ribbink • March 22, 2022 -
Retrieved from PharmaVOICE on March 21, 2022
BioMarin's new global head of advocacy is tackling the holy grail of patient engagement
In her new role, Dr. Roz is keeping her patient-first approach.
Taren Grom • March 21, 2022 -
Novartis' manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. Permission granted by Novartis.
How Novartis kept its supply chain intact during COVID-19
In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability.
Taren Grom • March 16, 2022 -
Image courtesy of Medigene.
Medigene's CEO on striking a collaboration deal with BioNTech
The two companies recently announced a $29 million collaboration.
Jared Whitlock • March 15, 2022 -
Permission granted by Sanjeev Luther.
Clearing hurdles in rare cancer drug development
Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.
Kim Ribbink • March 14, 2022 -
Stock via Getty Images
Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage
The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.
Taren Grom • March 14, 2022 -
Permission granted by Terry Weber
Biote CEO: Employers need to normalize women's health issues in the workforce
A survey by Biote reveals the impact of menopause on working women.
Robin Robinson • March 14, 2022 -
Image courtesy of Ultragenyx.
Ultragenyx's CEO on building a 'next-gen' rare disease company
How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.
Kim Ribbink • March 9, 2022 -
Permission granted by Ramona Sequeira.
Ramona Sequeira breaks PhRMA's glass ceiling
A few weeks ago, PhRMA, the industry’s largest trade group, announced that Sequeira has officially become chair of the organization’s board of directors. She is the first woman — and first woman of color — to take on the job.
Taren Grom • March 7, 2022 -
Permission granted by Andrew Hopkins.
Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
Meagan Parrish • March 4, 2022 -
Stock via Getty Images
Candel's CEO looks to help ignite a new era of cancer treatments
Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.
Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Why plasma derived therapies have a unique edge in rare diseases
Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.
Kim Ribbink • Feb. 25, 2022 -
Stock via Getty Images
Winning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
Taren Grom • Feb. 11, 2022 -
Permission granted by Mike Rea.
Innovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
Taren Grom • Feb. 9, 2022 -
Courtesy of Saniona
Saniona's CEO on why it takes a village to develop treatments for a rare disease
Saniona built its village by first hiring a head of patient advocacy.
Kim Ribbink • Feb. 8, 2022 -
Retrieved from Google image.
Gaining real-world results from a decentralized trial
Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.
Kelly Bilodeau • Feb. 8, 2022 -
Courtesy of 23andMe
Why 23andMe's first solo clinical trial is a big deal
It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come.
Taren Grom • Feb. 7, 2022 -
Permission granted by Mary Harmon
PTC's vice president of patient relations outlines the importance of patient input in rare disease R&D
You can't know what matters to rare disease patients unless you ask them.
Kim Ribbink • Feb. 3, 2022 -
Permission granted by Peter Anastasiou
New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
Taren Grom • Feb. 3, 2022 -
Retrieved from Rare Disease.org.
For the CEO of Travere, running a rare disease company is personal
To kick off Rare Disease month, we interview the CEO of Travere Therapeutics
Kim Ribbink • Feb. 1, 2022 -
Foghorn's CEO on why collaborations are key to unlocking precision medicine
With a major development deal under his belt, Adrian Gottschalk is helping the company advance its innovative platform.
Robin Robinson • Jan. 28, 2022
Previous
